Our clinical pipeline is centred on indications where stem cell therapy has shown the strongest evidence — knee osteoarthritis and degenerative disc disease — advanced through our Oracle and Delfi AI platforms. Additional programs in neurodegeneration are in preclinical development.
Our primary therapeutic area, addressing osteoarthritis and degenerative disc disease — chronic conditions affecting more than 600 million people globally, with no approved disease-modifying therapies. Both of our active clinical programs sit in this area.
iPSC-derived neuronal therapies for Parkinson's disease, building on our cell therapy modality to address one of the highest-unmet-need indications in neurology. Currently in preclinical development.
Both lead programs use autologous stem cell therapy, advanced through Oracle's cell therapy operating system.
Peer-reviewed data from our musculoskeletal programs demonstrate significant, sustained reductions in pain — alongside radiographic evidence of tissue regeneration.
For the full list of peer-reviewed publications, see Our Technology →
Our preclinical programs are evaluated end-to-end through Oracle and Delfi before advancing — applying the same decision-graded AI to next-generation indications beyond our current clinical portfolio.